Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Qutenza for Postherpetic Neuralgia
NCT00115310Phase 3Completed
- Sponsor
- NeurogesX
- Start
- Jun 2005
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of capsaicin in postherpetic neuralgia (PHN) (2 arms), sponsored by NeurogesX. Primary endpoint: Percent change from baseline in average pain for the past 24 hours Numeric Pain Rating Scale score. Started Jun 2005; status: completed.
02
Drugs
capsaicin
03
Conditions
postherpetic neuralgia (PHN)
Beyond the preview
Go deeper on NCT00115310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00115310.